Global and United States Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Report & Forecast 2022-2028

Global and United States Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Report & Forecast 2022-2028

Table of Contents
1 Study Coverage
1.1 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Introduction
1.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Outlook 2017 VS 2022 VS 2028
1.2.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in US$ Million for the Year 2017-2028
1.2.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Volume for the Year 2017-2028
1.3 United States Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Outlook 2017 VS 2022 VS 2028
1.3.1 United States Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in US$ Million for the Year 2017-2028
1.3.2 United States Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Volume for the Year 2017-2028
1.4 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.4.1 The Market Share of United States Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine in Global, 2017 VS 2022 VS 2028
1.4.2 The Growth Rate of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.5 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Dynamics
1.5.1 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Industry Trends
1.5.2 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Drivers
1.5.3 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Challenges
1.5.4 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Restraints
1.6 Study Objectives
1.7 Years Considered
2 Market by Type
2.1 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Segment by Type
2.1.1 Immune DTaP Vaccine
2.1.2 Therapy DTaP Vaccine
2.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Type
2.2.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Value, by Type (2017, 2022 & 2028)
2.2.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Volume, by Type (2017, 2022 & 2028)
2.2.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Average Selling Price (ASP) by Type (2017, 2022 & 2028)
2.3 United States Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Type
2.3.1 United States Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Value, by Type (2017, 2022 & 2028)
2.3.2 United States Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Volume, by Type (2017, 2022 & 2028)
2.3.3 United States Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Average Selling Price (ASP) by Type (2017, 2022 & 2028)
3 Market by Application
3.1 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Segment by Application
3.1.1 Adult
3.1.2 Pediatric
3.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Application
3.2.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Value, by Application (2017, 2022 & 2028)
3.2.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Volume, by Application (2017, 2022 & 2028)
3.3.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Average Selling Price (ASP) by Application (2017, 2022 & 2028)
3.3 United States Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Application
3.3.1 United States Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Value, by Application (2017, 2022 & 2028)
3.3.2 United States Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Volume, by Application (2017, 2022 & 2028)
3.3.3 United States Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Average Selling Price (ASP) by Application (2017, 2022 & 2028)
4 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Competitor Landscape by Company
4.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Company
4.1.1 Top Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Manufacturers Ranked by Revenue (2021)
4.1.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Manufacturer (2017-2022)
4.1.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Manufacturer (2017-2022)
4.1.4 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price by Manufacturer (2017-2022)
4.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Concentration Ratio (CR)
4.2.1 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Concentration Ratio (CR) (2017-2022)
4.2.2 Global Top 5 and Top 10 Largest Manufacturers of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine in 2021
4.2.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Manufacturing Base Distribution, Product Type
4.3.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Manufacturers, Headquarters and Distribution of Producing Region
4.3.2 Manufacturers Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Type
4.3.3 Date of International Manufacturers Enter into Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market
4.4 Manufacturers Mergers & Acquisitions, Expansion Plans
4.5 United States Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Company
4.5.1 Top Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Players in United States, Ranked by Revenue (2021)
4.5.2 United States Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Players (2020, 2021 & 2022)
4.5.3 United States Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Players (2020, 2021 & 2022)
5 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Region
5.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Region: 2017 VS 2022 VS 2028
5.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size in Volume by Region (2017-2028)
5.2.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Volume by Region: 2017-2022
5.2.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Volume Forecast by Region (2023-2028)
5.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size in Value by Region (2017-2028)
5.3.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Value by Region: 2017-2022
5.3.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Value by Region: 2023-2028
6 Segment in Region Level & Country Level
6.1 North America
6.1.1 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size YoY Growth 2017-2028
6.1.2 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Facts & Figures by Country (2017, 2022 & 2028)
6.1.3 U.S.
6.1.4 Canada
6.2 Asia-Pacific
6.2.1 Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size YoY Growth 2017-2028
6.2.2 Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Facts & Figures by Region (2017, 2022 & 2028)
6.2.3 China
6.2.4 Japan
6.2.5 South Korea
6.2.6 India
6.2.7 Australia
6.2.8 Taiwan
6.2.9 Indonesia
6.2.10 Thailand
6.2.11 Malaysia
6.2.12 Philippines
6.3 Europe
6.3.1 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size YoY Growth 2017-2028
6.3.2 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Facts & Figures by Country (2017, 2022 & 2028)
6.3.3 Germany
6.3.4 France
6.3.5 U.K.
6.3.6 Italy
6.3.7 Russia
6.4 Latin America
6.4.1 Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size YoY Growth 2017-2028
6.4.2 Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Facts & Figures by Country (2017, 2022 & 2028)
6.4.3 Mexico
6.4.4 Brazil
6.4.5 Argentina
6.5 Middle East and Africa
6.5.1 Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size YoY Growth 2017-2028
6.5.2 Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Facts & Figures by Country (2017, 2022 & 2028)
6.5.3 Turkey
6.5.4 Saudi Arabia
6.5.5 U.A.E
7 Company Profiles
7.1 Sanofi Pasteur
7.1.1 Sanofi Pasteur Corporation Information
7.1.2 Sanofi Pasteur Description and Business Overview
7.1.3 Sanofi Pasteur Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue and Gross Margin (2017-2022)
7.1.4 Sanofi Pasteur Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Products Offered
7.1.5 Sanofi Pasteur Recent Development
7.2 GlaxoSmithKline
7.2.1 GlaxoSmithKline Corporation Information
7.2.2 GlaxoSmithKline Description and Business Overview
7.2.3 GlaxoSmithKline Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue and Gross Margin (2017-2022)
7.2.4 GlaxoSmithKline Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Products Offered
7.2.5 GlaxoSmithKline Recent Development
7.3 Protein Sciences Corporation
7.3.1 Protein Sciences Corporation Corporation Information
7.3.2 Protein Sciences Corporation Description and Business Overview
7.3.3 Protein Sciences Corporation Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue and Gross Margin (2017-2022)
7.3.4 Protein Sciences Corporation Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Products Offered
7.3.5 Protein Sciences Corporation Recent Development
7.4 Novartis AG
7.4.1 Novartis AG Corporation Information
7.4.2 Novartis AG Description and Business Overview
7.4.3 Novartis AG Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue and Gross Margin (2017-2022)
7.4.4 Novartis AG Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Products Offered
7.4.5 Novartis AG Recent Development
7.5 Seqirus
7.5.1 Seqirus Corporation Information
7.5.2 Seqirus Description and Business Overview
7.5.3 Seqirus Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue and Gross Margin (2017-2022)
7.5.4 Seqirus Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Products Offered
7.5.5 Seqirus Recent Development
7.6 Merck Sharp & Dohme Corp
7.6.1 Merck Sharp & Dohme Corp Corporation Information
7.6.2 Merck Sharp & Dohme Corp Description and Business Overview
7.6.3 Merck Sharp & Dohme Corp Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue and Gross Margin (2017-2022)
7.6.4 Merck Sharp & Dohme Corp Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Products Offered
7.6.5 Merck Sharp & Dohme Corp Recent Development
7.7 Astellas Pharma US
7.7.1 Astellas Pharma US Corporation Information
7.7.2 Astellas Pharma US Description and Business Overview
7.7.3 Astellas Pharma US Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue and Gross Margin (2017-2022)
7.7.4 Astellas Pharma US Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Products Offered
7.7.5 Astellas Pharma US Recent Development
7.8 Pfizer Inc
7.8.1 Pfizer Inc Corporation Information
7.8.2 Pfizer Inc Description and Business Overview
7.8.3 Pfizer Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue and Gross Margin (2017-2022)
7.8.4 Pfizer Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Products Offered
7.8.5 Pfizer Inc Recent Development
7.9 Johnson & Johnson
7.9.1 Johnson & Johnson Corporation Information
7.9.2 Johnson & Johnson Description and Business Overview
7.9.3 Johnson & Johnson Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue and Gross Margin (2017-2022)
7.9.4 Johnson & Johnson Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Products Offered
7.9.5 Johnson & Johnson Recent Development
7.10 Lanzhou Institute of Biological Products Co., Ltd
7.10.1 Lanzhou Institute of Biological Products Co., Ltd Corporation Information
7.10.2 Lanzhou Institute of Biological Products Co., Ltd Description and Business Overview
7.10.3 Lanzhou Institute of Biological Products Co., Ltd Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue and Gross Margin (2017-2022)
7.10.4 Lanzhou Institute of Biological Products Co., Ltd Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Products Offered
7.10.5 Lanzhou Institute of Biological Products Co., Ltd Recent Development
7.11 AstraZeneca
7.11.1 AstraZeneca Corporation Information
7.11.2 AstraZeneca Description and Business Overview
7.11.3 AstraZeneca Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue and Gross Margin (2017-2022)
7.11.4 AstraZeneca Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Products Offered
7.11.5 AstraZeneca Recent Development
7.12 Emergent BioSolutions Inc
7.12.1 Emergent BioSolutions Inc Corporation Information
7.12.2 Emergent BioSolutions Inc Description and Business Overview
7.12.3 Emergent BioSolutions Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue and Gross Margin (2017-2022)
7.12.4 Emergent BioSolutions Inc Products Offered
7.12.5 Emergent BioSolutions Inc Recent Development
8 Industry Chain and Sales Channels Analysis
8.1 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Industry Chain Analysis
8.2 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Key Raw Materials
8.2.1 Key Raw Materials
8.2.2 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Distributors
8.3 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Production Mode & Process
8.4 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales and Marketing
8.4.1 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Channels
8.4.2 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Distributors
8.5 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Customers
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
List of Tables
Table 1. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine CAGR in Value, United States VS Global, 2017 VS 2022 VS 2028
Table 2. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Trends
Table 3. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Drivers
Table 4. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Challenges
Table 5. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Restraints
Table 6. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type: 2017 VS 2022 VS 2028 (US$ Million)
Table 7. United States Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type: 2017 VS 2022 VS 2028 (US$ Million)
Table 8. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application: 2017 VS 2022 VS 2028 (US$ Million)
Table 9. United States Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application: 2017 VS 2022 VS 2028 (US$ Million)
Table 10. Top Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Manufacturers in Global Market, Ranking by Revenue (2021)
Table 11. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Manufacturer, (US$ Million), 2017-2022
Table 12. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Share by Manufacturer, 2017-2022
Table 13. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Manufacturer, (K Doses), 2017-2022
Table 14. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Share by Manufacturer, 2017-2022
Table 15. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price by Manufacturer (2017-2022) & (USD/Dose)
Table 16. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 17. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine as of 2021)
Table 18. Top Players of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine in Global Market, Headquarters and Distribution of Producing Region
Table 19. Manufacturers Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Type
Table 20. Date of International Manufacturers Enter into Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market
Table 21. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 22. Top Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Players in United States Market, Ranking by Revenue (2021)
Table 23. United States Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Players, (US$ Million), 2020, 2021 & 2022
Table 24. United States Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue Share by Players, 2020, 2021 & 2022
Table 25. United States Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Players, (K Doses), 2020, 2021 & 2022
Table 26. United States Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Share by Players, 2020, 2021 & 2022
Table 27. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Region (US$ Million): 2017 VS 2022 VS 2028
Table 28. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Volume by Region (2017-2022) & (K Doses)
Table 29. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Volume Forecast by Region (2023-2028) & (K Doses)
Table 30. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Value by Region (2017-2022) & (US$ Million)
Table 31. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Value Forecast by Region (2023-2028) & (US$ Million)
Table 32. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Volume by Country (2017-2028) & (K Doses)
Table 33. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Value by Country (2017-2028) & (US$ Million)
Table 34. Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Volume by Region (2017-2028) & (K Doses)
Table 35. Asia Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Value by Region (2017-2028) & (US$ Million)
Table 36. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Volume by Country (2017-2028) & (K Doses)
Table 37. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Value by Country (2017-2028) & (US$ Million)
Table 38. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Volume by Country (2017-2028) & (K Doses)
Table 39. Latin Americaa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Value by Country (2017-2028) & (US$ Million)
Table 40. Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Volume by Country (2017-2028) & (K Doses)
Table 41. Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Value by Country (2017-2028) & (US$ Million)
Table 42. Sanofi Pasteur Corporation Information
Table 43. Sanofi Pasteur Description and Business Overview
Table 44. Sanofi Pasteur Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 45. Sanofi Pasteur Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product
Table 46. Sanofi Pasteur Recent Development
Table 47. GlaxoSmithKline Corporation Information
Table 48. GlaxoSmithKline Description and Business Overview
Table 49. GlaxoSmithKline Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 50. GlaxoSmithKline Product
Table 51. GlaxoSmithKline Recent Development
Table 52. Protein Sciences Corporation Corporation Information
Table 53. Protein Sciences Corporation Description and Business Overview
Table 54. Protein Sciences Corporation Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 55. Protein Sciences Corporation Product
Table 56. Protein Sciences Corporation Recent Development
Table 57. Novartis AG Corporation Information
Table 58. Novartis AG Description and Business Overview
Table 59. Novartis AG Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 60. Novartis AG Product
Table 61. Novartis AG Recent Development
Table 62. Seqirus Corporation Information
Table 63. Seqirus Description and Business Overview
Table 64. Seqirus Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 65. Seqirus Product
Table 66. Seqirus Recent Development
Table 67. Merck Sharp & Dohme Corp Corporation Information
Table 68. Merck Sharp & Dohme Corp Description and Business Overview
Table 69. Merck Sharp & Dohme Corp Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 70. Merck Sharp & Dohme Corp Product
Table 71. Merck Sharp & Dohme Corp Recent Development
Table 72. Astellas Pharma US Corporation Information
Table 73. Astellas Pharma US Description and Business Overview
Table 74. Astellas Pharma US Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 75. Astellas Pharma US Product
Table 76. Astellas Pharma US Recent Development
Table 77. Pfizer Inc Corporation Information
Table 78. Pfizer Inc Description and Business Overview
Table 79. Pfizer Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 80. Pfizer Inc Product
Table 81. Pfizer Inc Recent Development
Table 82. Johnson & Johnson Corporation Information
Table 83. Johnson & Johnson Description and Business Overview
Table 84. Johnson & Johnson Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 85. Johnson & Johnson Product
Table 86. Johnson & Johnson Recent Development
Table 87. Lanzhou Institute of Biological Products Co., Ltd Corporation Information
Table 88. Lanzhou Institute of Biological Products Co., Ltd Description and Business Overview
Table 89. Lanzhou Institute of Biological Products Co., Ltd Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 90. Lanzhou Institute of Biological Products Co., Ltd Product
Table 91. Lanzhou Institute of Biological Products Co., Ltd Recent Development
Table 92. AstraZeneca Corporation Information
Table 93. AstraZeneca Description and Business Overview
Table 94. AstraZeneca Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 95. AstraZeneca Product
Table 96. AstraZeneca Recent Development
Table 97. Emergent BioSolutions Inc Corporation Information
Table 98. Emergent BioSolutions Inc Description and Business Overview
Table 99. Emergent BioSolutions Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 100. Emergent BioSolutions Inc Product
Table 101. Emergent BioSolutions Inc Recent Development
Table 102. Key Raw Materials Lists
Table 103. Raw Materials Key Suppliers Lists
Table 104. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Customers List
Table 105. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Distributors List
Table 106. Research Programs/Design for This Report
Table 107. Key Data Information from Secondary Sources
Table 108. Key Data Information from Primary Sources
List of Figures
Figure 1. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Picture
Figure 2. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue, (US$ Million), 2017 VS 2022 VS 2028
Figure 3. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size 2017-2028 (US$ Million)
Figure 4. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales 2017-2028 (K Doses)
Figure 5. United States Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue, (US$ Million), 2017 VS 2022 VS 2028
Figure 6. United States Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size 2017-2028 (US$ Million)
Figure 7. United States Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales 2017-2028 (K Doses)
Figure 8. United States Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Share in Global, in Value (US$ Million) 2017-2028
Figure 9. United States Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Share in Global, in Volume (K Doses) 2017-2028
Figure 10. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Report Years Considered
Figure 11. Product Picture of Immune DTaP Vaccine
Figure 12. Product Picture of Therapy DTaP Vaccine
Figure 13. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Share by Type in 2022 & 2028
Figure 14. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Value by Type (2017-2028) & (US$ Million)
Figure 15. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share in Value by Type (2017-2028)
Figure 16. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2017-2028) & (K Doses)
Figure 17. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share in Volume by Type (2017-2028)
Figure 18. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price by Type (2017-2028) & (USD/Dose)
Figure 19. United States Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Share by Type in 2022 & 2028
Figure 20. United States Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Value by Type (2017-2028) & (US$ Million)
Figure 21. United States Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share in Value by Type (2017-2028)
Figure 22. United States Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2017-2028) & (K Doses)
Figure 23. United States Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share in Volume by Type (2017-2028)
Figure 24. United States Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price by Type (2017-2028) & (USD/Dose)
Figure 25. Product Picture of Adult
Figure 26. Product Picture of Pediatric
Figure 27. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Share by Application in 2022 & 2028
Figure 28. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Value by Application (2017-2028) & (US$ Million)
Figure 29. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share in Value by Application (2017-2028)
Figure 30. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2017-2028) & (K Doses)
Figure 31. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share in Volume by Application (2017-2028)
Figure 32. Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price by Application (2017-2028) & (USD/Dose)
Figure 33. United States Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Share by Application in 2022 & 2028
Figure 34. United States Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Value by Application (2017-2028) & (US$ Million)
Figure 35. United States Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share in Value by Application (2017-2028)
Figure 36. United States Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2017-2028) & (K Doses)
Figure 37. United States Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Market Share in Volume by Application (2017-2028)
Figure 38. United States Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price by Application (2017-2028) & (USD/Dose)
Figure 39. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Volume Growth Rate 2017-2028 (K Doses)
Figure 40. North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 41. U.S. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 42. Canada Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 43. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Volume Growth Rate 2017-2028 (K Doses)
Figure 44. Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 45. Germany Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 46. France Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 47. U.K. Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 48. Italy Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 49. Russia Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 50. Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Volume Growth Rate 2017-2028 (K Doses)
Figure 51. Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 52. China Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 53. Japan Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 54. South Korea Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 55. India Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 56. Australia Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 57. Taiwan Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 58. Indonesia Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 59. Thailand Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 60. Malaysia Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 61. Philippines Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 62. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Volume Growth Rate 2017-2028 (K Doses)
Figure 63. Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 64. Mexico Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Value Growth Rate (2017-2028) & (US$ Million)

• Clinical Results in Diabetics To Be Boosted By Smart Artificial Beta Cells

For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…

• High-speed Data Transmission And High Volume Needs Propel Fiber Optic Connectors Market

Fiber optic connectors are a substantial fragment of the global telecommunication industry. Optical fibers are joined using fiber optic connectors, which allow the light conduction between two consecutive optical fibers. An additional im…

• Extensive Use of Digital Technologies for Diagnostic Applications To Boost Global Optical Imaging Market

The global optical imaging system market is predicted to reach US$ 3 billion by 2024. It is expected to grow at a stable rate and will post a CAGR of more than 8% in the coming years. The growing market infiltration of digital …

• Foremost Trends In Global Pet Care Market

The global pet care market is foretold to improve in the forthcoming years as matched to the preceding years and will showcase better sales in various market segments. It is estimated that the global pet care market will grow at a CAGR o…

• China To Review Its Food Security Laws

China has arisen as the globe’s firmest developing economy. In addition, China brags about the biggest population pool in the world. In recent times, the one child policy in the republic was terminated. This is anticipated to upsur…

Global Antioxidant Vitamins Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 100

The global Antioxidant Vitamins market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Antioxidant Vitamins is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Antioxidant Vitamins is estimated to increase from $ million in 2023 to reach $ millio......

Global Clavulanate Potassium Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 86

The global Clavulanate Potassium market was valued at US$ 446.6 million in 2023 and is anticipated to reach US$ 637.2 million by 2030, witnessing a CAGR of 5.2% during The forecast period 2024-2030. North American market for Clavulanate Potassium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Clavulanate Potassium is estimated to increase from $ million in 2023......

Global Amoxicillin Sodium Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 84

The global Amoxicillin Sodium market was valued at US$ 460.9 million in 2023 and is anticipated to reach US$ 735.1 million by 2030, witnessing a CAGR of 7.0% during The forecast period 2024-2030. North American market for Amoxicillin Sodium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Amoxicillin Sodium is estimated to increase from $ million in 2023 to reach......

Global Melatonin Supplements Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 106

The global Melatonin Supplements market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Melatonin Supplements is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Melatonin Supplements is estimated to increase from $ million in 2023 to reach $ mil......

Global Sleeping Pills (Prescription Drugs) Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 93

The global Sleeping Pills (Prescription Drugs) market was valued at US$ 1022.3 million in 2023 and is anticipated to reach US$ 1437.8 million by 2030, witnessing a CAGR of 4.9% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical......

Global Sleeping Pills Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 94

The global Sleeping Pills market was valued at US$ 2042.3 million in 2023 and is anticipated to reach US$ 2979.5 million by 2030, witnessing a CAGR of 3.8% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estim......

Global Zinc Oral Drops Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85

The global Zinc Oral Drops market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Zinc Oral Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Zinc Oral Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a......

Global Zinc Drops Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85

The global Zinc Drops market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Zinc Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Zinc Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % duri......

Global Anti-Infectives Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 78

The global Anti-Infectives market was valued at US$ 22700 million in 2023 and is anticipated to reach US$ 27480 million by 2030, witnessing a CAGR of 2.3% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estima......

We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s. Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors. Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business. Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision. Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us. Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done. Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )

• Ad Hoc
• Pay - as - you - go / Bucket Subscriptions
• Fixed Cost for #of reports
• Customize / Personalize as per your needs